We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Artificial Sweeteners May Promote Development of Glucose Intolerance and Weight Gain

By LabMedica International staff writers
Posted on 01 Oct 2014
Recently published findings have stirred a controversy by indicating that noncaloric artificial sweeteners (NAS), a key components of diet drinks and foods, actually promote development of glucose intolerance, metabolic disease, and obesity by causing profound changes in the composition and function of the organisms that make up the intestinal microbiome (gut microbiota).

Investigators at the Weizmann Institute of Science (Rehovot, Israel) worked with mouse models as well as evaluating data accumulated by the Personalized Nutrition Project, a large human trial probing the connection between nutrition and the microbiota.

They reported in the September 17, 2014, online edition of the journal Nature that consumption of commonly used NAS formulations drove the development of glucose intolerance through induction of compositional and functional alterations to the intestinal microbiota. More...
These NAS-mediated deleterious metabolic effects were reversed by antibiotic treatment, and were fully transferable to germ-free mice upon fecal transplantation of microbiota configurations from NAS-consuming mice. Similar changes were observed in anaerobic cultures of organisms from the gut microbiota that were grown in the presence of NAS.

The investigators identified NAS-altered microbial metabolic pathways that were linked to host susceptibility to metabolic disease, and demonstrated similar NAS-induced microbial imbalance and glucose intolerance in healthy human subjects.

Senior author Dr. Eran Elinav, professor of immunology at the Weizmann Institute of Science, said, "Certain bacteria in the guts of those who developed glucose intolerance reacted to the chemical sweeteners by secreting substances that then provoked an inflammatory response similar to sugar overdose, promoting changes in the body’s ability to utilize sugar. Our relationship with our own individual mix of gut bacteria is a huge factor in determining how the food we eat affects us. Especially intriguing is the link between use of artificial sweeteners, through the bacteria in our guts, to a tendency to develop the very disorders they were designed to prevent; this calls for reassessment of today’s massive, unsupervised consumption of these substances.”

Related Links:

Weizmann Institute of Science
Personalized Nutrition Project



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.